Alterity Therapeutics Limited
PRNAF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$55.72M
Close$
$0.12
50.4% downside
Current Fair Value
50.4% downsideOvervalued by 50.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $55.72 Million |
|---|---|
| Enterprise Value | $18.59 Million |
| Earnings per Share | $-0.11 |
| Beta | -0.04 |
| Outstanding Shares | 217,508,862 |
Return
| Return on Equity | -74.85% |
|---|---|
| Return on Assets | -69.49% |
| Return on Invested Capital | -91.65% |
Valuation & Multiples
| P/E Ratio | -2.31 |
|---|---|
| PEG | -1.28 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.01 |
| Enterprise Value to EBIT | -0.47 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$-0.01
Consensus analyst estimateRevenue Estimate
$2.27 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$-0.00
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Alterity Therapeutics Ltd
11 employees
CEO: Geoffrey Kempler
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among oth...